-

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR MOONLAKE IMMUNOTHERAPEUTICS (MLTX) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS

What Happened?

On September 28, 2025, MoonLake Immunotherapeutics announced disappointing Phase 3 results for its only drug candidate, sonelokimab (“SLK”), revealing that SLK failed to match the efficacy of its competitor, Union Chimique Belge’s bimekizumab-bkz (“BIMZELX”). The Company had repeatedly promoted SLK’s nanobody structure as superior to other monoclonal antibodies—while allegedly failing to disclose it targeted the same molecules and lacked proven advantages.

Following the news, MoonLake’s stock fell $55.74, or 89.9%, to close at $6.24 per share on September 29, 2025, and thereby harming investors.

What Is the Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) that SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired MoonLake common stock during the Class Period, you may move the Court no later than December 15, 2025 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us to Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Charles Linehan, Esq.
Glancy Prongay & Murray LLP
1925 Century Park East, Suite 2100
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Glancy Prongay & Murray LLP

NASDAQ:MLTX

Release Versions

Contacts

Glancy Prongay & Murray LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

More News From Glancy Prongay & Murray LLP

Deadline Alert: Lennar Corporation Investors Have Until January 11, 2027 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

LOS ANGELES--(BUSINESS WIRE)--Investors in Lennar Corporation ("Lennar" or the "Company") (NYSE: LEN) have until January 11, 2027 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Lennar Corporation securities between February 7, 2025 and October 2, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline. The Lennar Corporation case...

Securities Fraud Class Action Filed Against Nuscale Power Corporation: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

LOS ANGELES--(BUSINESS WIRE)--A securities fraud class action lawsuit has been filed against Nuscale Power Corporation ("Nuscale" or the "Company") (NYSE: SMR) on behalf of investors who purchased or otherwise acquired the Company's securities between February 27, 2026 and September 10, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced the filing. The Nuscale Power Corporation case, Chiu-Yueh Chang v. NuScale Power Corporation et al., was filed on November 11, 202...

Lost Money on Evolution Metals & Technologies Corp. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 25.78% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Evolution Metals & Technologies Corp. ("Evolution Metals" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Evolution Metals & Technologies Corp. (NASDAQ: EMAT) investors into whether the Company may have violated the federal securities laws.Investors who lost money on Evolution Metals & Technologies Co...
Back to Newsroom